$CGEN Balance Sheet | Understand Stock

$CGEN

$1.88 -$0.06 (3.35%) Close

$CGEN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q4 FY2025 As of Dec 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q4 FY2017 As of Dec 31, 2017	Q4 FY2016 As of Dec 31, 2016	Q4 FY2015 As of Dec 31, 2015	Q4 FY2014 As of Dec 31, 2014	Q4 FY2013 As of Dec 31, 2013	Q4 FY2012 As of Dec 31, 2012	Q4 FY2011 As of Dec 31, 2011
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
Restricted cash
Short-term bank deposits
Investment in Evogene
Investment in marketable securities
Trade receivables
Other accounts receivable and prepaid expenses
Total current assets

Investment in Evogene
NON-CURRENT ASSETS:
Long-term bank deposits
Restricted long-term bank deposits
Long-term prepaid expenses
Severance pay fund
Operating lease right of use asset
Property and equipment, net
Total non-current assets

Total assets

LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade payables
Short-term deferred participation in R&D expenses
Deferred revenues
Research and development funding arrangement
Current maturity of operating lease liability
Other accounts payable and accrued expenses
Accrued expenses
Employees and related accruals
Total current liabilities

NON-CURRENT LIABILITIES:
Research and development funding arrangement
Deferred revenues
Long-term deferred participation in R&D expenses
Operating lease liability
Accrued severance pay
Total non-current liabilities
Research and development funding arrangements and others

SHAREHOLDERS' EQUITY:
Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2025 and 2024; 94,553,191 and 89,541,246 shares issued and outstanding at December 31, 2025 and 2024, respectively.
Additional paid-in capital
Accumulated other comprehensive income
Accumulated deficit
Total shareholders’ equity
Total liabilities and shareholders’ equity

Comments